Real-world outcomes of advanced melanoma patients not represented in phase III trials

Source: MDLinx, July 2020

Researchers used nationwide population-based registry to provide evidence on systemically treated patients with advanced melanoma not represented in phase III trials to support clinical decision-making.

Analysis were conducted on advanced melanoma individuals diagnosed between 2014 and 2017 in the Netherlands, treated with immune- or targeted therapy, who met greater than or equal to 1 trial exclusion criteria.

Of the 2,536 systemically treated patients with advanced melanoma, 1,004 (40%) patients were not eligible for Phase III trials.

READ THE ORIGINAL FULL ARTICLE